Frankfurt
29.12.25 | 09:20
0,004 Euro
+600,00 % +0,003
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,003 | 0,015 | 16:54 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.12. | Revive Therapeutics Ltd: Revive Therapeutics primes the pump on Bucillamine | 3 | Stockwatch | ||
| 15.12. | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | 108 | GlobeNewswire (Europe) | TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| 21.11. | Revive Therapeutics Ltd: Revive talks DRDC study on bucillamine for nerve agents | 3 | Stockwatch | ||
| 21.11. | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | 720 | GlobeNewswire (Europe) | TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| REVIVE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.09. | Revive Therapeutics Ltd: Revive Therapeutics closes second tranche of financing | 12 | Stockwatch | ||
| 19.09. | Revive Therapeutics Ltd.: Revive Therapeutics Announces Closing of Second Tranche of Private Placement | 2 | GlobeNewswire (USA) | ||
| 08.09. | Revive Therapeutics announces extension of proposed private placement | 5 | Seeking Alpha | ||
| 06.09. | Revive Therapeutics Ltd: Revive extends $650,000 private placement | 3 | Stockwatch | ||
| 06.09. | Revive Therapeutics Ltd.: Revive Therapeutics Announces Extension of Proposed Private Placement | 5 | GlobeNewswire (USA) | ||
| 12.08. | Revive Therapeutics Ltd: Revive closes $60,900 first tranche of placement | 11 | Stockwatch | ||
| 12.08. | Revive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement | 286 | GlobeNewswire (Europe) | TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing... ► Artikel lesen | |
| 31.07. | Revive Therapeutics Ltd: Revive Therapeutics arranges financing, debt settlement | 3 | Stockwatch | ||
| 31.07. | Revive Therapeutics Ltd.: Revive Therapeutics Announces Proposed Private Placement and Debt Settlement | 261 | GlobeNewswire (Europe) | TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing... ► Artikel lesen | |
| 09.07. | Revive Therapeutics Ltd: Revive has no future plans yet with Defence R&D | 14 | Stockwatch | ||
| 08.07. | Revive Therapeutics Ltd.: Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study | 2 | GlobeNewswire (USA) | ||
| 12.05. | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | 403 | GlobeNewswire (Europe) | TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| 10.04. | Revive Therapeutics Ltd.: Revive Therapeutics to Investigate Bucillamine's Potential in Cancer Treatment | 451 | GlobeNewswire (Europe) | TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| 01.04. | Revive Therapeutics Ltd.: Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program | 483 | GlobeNewswire (Europe) | TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| 19.03. | Revive Therapeutics Ltd.: Revive Therapeutics Announces Results of Annual Shareholder Meeting | 949 | GlobeNewswire (Europe) | TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| 03.02. | Revive Therapeutics Ltd.: Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures | 554 | GlobeNewswire (Europe) | TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | +0,81 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| EVOTEC | 5,452 | +4,32 % | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution |
EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| BB BIOTECH | 48,650 | -1,72 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| MEDIGENE | 0,023 | -12,78 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 38,995 | -0,32 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| CUREVAC | 3,594 | +5,83 % | Morgen-Update: Curevac-Aktie auffällig ruhig - steht der Ausbruch kurz bevor? | ||
| MODERNA | 26,255 | -4,14 % | Forget Moderna Stock, This is a Much Better Buy | ||
| VALNEVA | 3,760 | +3,75 % | Morgen-Update: Valneva-Aktie zieht durch - kommt jetzt die große Rallye? | ||
| AMGEN | 281,90 | +0,28 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| EPIGENOMICS | 0,894 | +0,45 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 5,704 | -1,20 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| BIOGEN | 150,90 | +1,75 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| BIOFRONTERA | 2,400 | +0,84 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,440 | +2,09 % | EQS-News: Heidelberg Pharma AG: Brief des Vorstandsvorsitzenden | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma: Brief des Vorstandsvorsitzenden
17.12.2025 / 09:21 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| ILLUMINA | 114,36 | -1,00 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen |
REVIVE THERAPEUTICS LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,004 Euro und damit +600,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVE THERAPEUTICS LTD finden Sie auf Wallstreet Online.